LXEO

Price & events

Pipeline stages · 2 programs

Pipeline · 2 trials · 2 upcoming

Catalyst news & presentations · 16

• first half of 2028Guided 55%regulatory submissionFiled (NDA/BLA)LX2006 · BLA submission under accelerated approval pathwaySEC 8-K
• second half of 2027Guided 55%readoutPhase 3LX2006 · Topline efficacy readout of SUNRISE-FA 2 pivotal trial at 6 months post-treatmentSEC 8-K
• Q4 2026Guided 70%readoutPhase 1/2LX2020 · 12-month data for all high-dose participantsSEC 8-K
• 2026-08-13earningsEarningsEarnings releaseyahoo
• end of June 2026trial initiationsecondaryPhase 3LX2006 · First patient enrollment in SUNRISE-FA 2 pivotal trialSEC 8-K
• 2026-06-15fda agreementLX2006 · FDA agreed to pivotal trial design for accelerated approval, removed co-primary endpoint requirementSEC 8-K
• May 2026conferencedata presentationsecondaryPhase 1/2LX2006 · Present interim clinical data and preclinical updates at ASGCTSEC 8-K
• By End of 2025 or Early 2026trial initiationsecondaryPhase 3LX2006 · Initiate registrational studySEC 8-K
• 2025-10-16fda agreementLX2006 · FDA indicated openness to BLA submission for accelerated approval using pooled data from ongoing Phase I/II and planned pivotal study, subject to additional manufacturing comparability and nonclinical requirements.SEC 8-K
• mid-2025readoutPhase 1/2LX2006 · High-dose dataSEC 8-K
• 2025-04-07fda agreementLX2006 · FDA alignment on co-primary endpoints for accelerated approval: 10% LVMI reduction and any frataxin increaseSEC 8-K
• late first quarter or early second quarter of 2025readoutPhase 1/2LX2020 · Cohort 1 data from LX2020 Phase 1/2 trial for PKP2-ACMSEC 8-K
• late Q1 / early Q2 2025readoutPhase 1/2LX2020 · Initial clinical data on protein expression and safetySEC 8-K
• late Q1 / early Q2 2025readoutPhase 1/2LX2006 · Initial clinical data on protein expression and safetySEC 8-K
• Fall 2024conferencedata presentationsecondaryPhase 1/2LX2006 · Share further interim data including cardiac biopsy from Cohort 2 at scientific conference.SEC 8-K
• October 2024conferencedata presentationsecondaryPhase 1/2LX1001 · Present data from LX1001 at Clinical Trials on Alzheimer's Disease conferenceSEC 8-K